IL269522A - - Google Patents

Info

Publication number
IL269522A
IL269522A IL26952219A IL26952219A IL269522A IL 269522 A IL269522 A IL 269522A IL 26952219 A IL26952219 A IL 26952219A IL 26952219 A IL26952219 A IL 26952219A IL 269522 A IL269522 A IL 269522A
Authority
IL
Israel
Application number
IL26952219A
Other languages
English (en)
Other versions
IL269522B1 (en
IL269522B2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901027A external-priority patent/AU2017901027A0/en
Application filed filed Critical
Publication of IL269522A publication Critical patent/IL269522A/en
Publication of IL269522B1 publication Critical patent/IL269522B1/en
Publication of IL269522B2 publication Critical patent/IL269522B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL269522A 2017-03-23 2018-03-23 Combination therapy for the treatment or prevention of tumours IL269522B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017901027A AU2017901027A0 (en) 2017-03-23 Combination Therapy
PCT/AU2018/050277 WO2018170559A1 (en) 2017-03-23 2018-03-23 Combination therapy for the treatment or prevention of tumours

Publications (3)

Publication Number Publication Date
IL269522A true IL269522A (https=) 2019-11-28
IL269522B1 IL269522B1 (en) 2024-01-01
IL269522B2 IL269522B2 (en) 2024-05-01

Family

ID=63583892

Family Applications (1)

Application Number Title Priority Date Filing Date
IL269522A IL269522B2 (en) 2017-03-23 2018-03-23 Combination therapy for the treatment or prevention of tumours

Country Status (27)

Country Link
US (1) US11213506B2 (https=)
EP (1) EP3600281B1 (https=)
JP (1) JP6905075B2 (https=)
KR (1) KR102228055B1 (https=)
CN (1) CN110461324A (https=)
AU (1) AU2018238202C1 (https=)
CA (1) CA3056685C (https=)
DK (1) DK3600281T3 (https=)
EA (1) EA201992220A1 (https=)
ES (1) ES2953575T3 (https=)
FI (1) FI3600281T3 (https=)
HR (1) HRP20230936T1 (https=)
HU (1) HUE063299T2 (https=)
IL (1) IL269522B2 (https=)
LT (1) LT3600281T (https=)
MX (1) MX391826B (https=)
MY (1) MY197427A (https=)
PH (1) PH12019502132A1 (https=)
PL (1) PL3600281T3 (https=)
PT (1) PT3600281T (https=)
RS (1) RS64472B1 (https=)
SG (1) SG11201907891XA (https=)
SI (1) SI3600281T1 (https=)
SM (1) SMT202300272T1 (https=)
UA (1) UA125614C2 (https=)
WO (1) WO2018170559A1 (https=)
ZA (1) ZA201906001B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006326872C1 (en) * 2005-12-23 2018-05-17 QBiotics Pty Ltd Tiglien-3-one derivatives
TWI707038B (zh) 2013-08-05 2020-10-11 美商扭轉生物科技有限公司 重新合成之基因庫
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
KR20180050411A (ko) 2015-09-18 2018-05-14 트위스트 바이오사이언스 코포레이션 올리고핵산 변이체 라이브러리 및 그의 합성
KR102794025B1 (ko) 2015-09-22 2025-04-09 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
CN110892485B (zh) 2017-02-22 2024-03-22 特韦斯特生物科学公司 基于核酸的数据存储
US10696965B2 (en) 2017-06-12 2020-06-30 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
CN111566125A (zh) 2017-09-11 2020-08-21 特韦斯特生物科学公司 Gpcr结合蛋白及其合成
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
KR102804057B1 (ko) 2018-01-04 2025-05-07 트위스트 바이오사이언스 코포레이션 Dna 기반 디지털 정보 저장
CA3100739A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
US12357959B2 (en) 2018-12-26 2025-07-15 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
CA3131691A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
CN113766930B (zh) 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
EP3952858B1 (en) * 2019-04-12 2025-12-17 QBiotics Pty Ltd Method of treating tumours
MX2021015673A (es) 2019-06-19 2022-02-03 QBiotics Pty Ltd Alteracion de biopelicula.
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
JP2022548309A (ja) 2019-09-23 2022-11-17 ツイスト バイオサイエンス コーポレーション Crth2のバリアント核酸ライブラリー
WO2021061842A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for single domain antibodies
IL293670A (en) 2019-12-09 2022-08-01 Twist Bioscience Corp Variable nucleic acid libraries for adenosine receptors
WO2022159620A1 (en) 2021-01-21 2022-07-28 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
KR102774792B1 (ko) 2021-05-06 2025-03-05 한국과학기술연구원 가시광선에 의해 활성화되는 항암 면역치료용 나노입자 및 이의 용도
CN118451065A (zh) * 2021-12-21 2024-08-06 Q生物股份有限公司 结晶中间体
MX2024010046A (es) * 2022-02-17 2024-08-26 QBiotics Pty Ltd Terapias de combinacion.
JP2026500534A (ja) * 2022-12-21 2026-01-07 キューバイオティクス プロプライアタリー リミティド 結晶形態及びその製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006268148B2 (en) * 2005-07-13 2012-11-01 Salvia Sciences, Inc. Ester prodrugs of prostratin and related phorbol compounds
AU2006326872C1 (en) * 2005-12-23 2018-05-17 QBiotics Pty Ltd Tiglien-3-one derivatives
RS58532B1 (sr) 2013-04-18 2019-04-30 Qbiotics Ltd Metodi i kompozicije za zarastanje rana
WO2015133596A1 (ja) * 2014-03-07 2015-09-11 国立大学法人京都大学 細胞培養用組成物
AU2015289081B2 (en) 2014-07-16 2020-02-06 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
JP6991857B2 (ja) 2014-10-10 2022-01-13 イデラ ファーマシューティカルズ インコーポレイテッド Tlr9アゴニストをチェックポイント阻害剤と共に用いるがんの治療
CN104926758A (zh) * 2015-05-22 2015-09-23 南京泽朗医药科技有限公司 斑籽素的制备方法及其在抗白血病药物中的应用
CN108026026B (zh) * 2015-08-03 2021-02-09 夸德里加生物科学公司 作为化疗剂的β-取代的β-氨基酸和类似物及其应用

Also Published As

Publication number Publication date
ES2953575T3 (es) 2023-11-14
MX2019011221A (es) 2019-11-01
NZ756754A (en) 2024-02-23
HRP20230936T1 (hr) 2023-11-24
AU2018238202C1 (en) 2025-06-05
PL3600281T3 (pl) 2023-09-11
CA3056685A1 (en) 2018-09-27
UA125614C2 (uk) 2022-05-04
CN110461324A (zh) 2019-11-15
EP3600281A1 (en) 2020-02-05
AU2018238202A8 (en) 2024-03-28
KR102228055B1 (ko) 2021-03-16
RS64472B1 (sr) 2023-09-29
AU2018238202B2 (en) 2024-03-28
SG11201907891XA (en) 2019-09-27
US20200030279A1 (en) 2020-01-30
SI3600281T1 (sl) 2023-10-30
ZA201906001B (en) 2023-12-20
WO2018170559A1 (en) 2018-09-27
JP2020511512A (ja) 2020-04-16
CA3056685C (en) 2024-01-16
MY197427A (en) 2023-06-16
DK3600281T3 (da) 2023-08-14
IL269522B1 (en) 2024-01-01
HUE063299T2 (hu) 2024-01-28
PT3600281T (pt) 2023-09-04
EP3600281A4 (en) 2020-03-18
SMT202300272T1 (it) 2023-09-06
EP3600281B1 (en) 2023-05-31
KR20190126431A (ko) 2019-11-11
US11213506B2 (en) 2022-01-04
EA201992220A1 (ru) 2020-02-11
LT3600281T (lt) 2023-09-11
MX391826B (es) 2025-03-21
JP6905075B2 (ja) 2021-07-21
FI3600281T3 (fi) 2023-08-24
PH12019502132A1 (en) 2020-07-06
AU2018238202A1 (en) 2019-09-19
IL269522B2 (en) 2024-05-01
BR112019019748A2 (pt) 2020-04-14

Similar Documents

Publication Publication Date Title
IL269522A (https=)
BR122021024397A2 (https=)
BR122021000189A2 (https=)
BR112020006084A8 (https=)
BR122022025811B8 (https=)
BR202018014992U2 (https=)
BR122021023687A2 (https=)
BR122021014832A2 (https=)
BR122022003520A2 (https=)
BR112020008820A2 (https=)
BR202017025154U2 (https=)
BR102017023327A2 (https=)
BR202017021228U2 (https=)
BR202017020981U2 (https=)
BR202017017068U2 (https=)
BR202017016984U2 (https=)
BR202017016924U2 (https=)
BR102017015495A2 (https=)
BR202017012548U2 (https=)
BR202017011220U2 (https=)
BR202017010814U2 (https=)
BR202017010373U2 (https=)
BR202017009870U2 (https=)
BR202017006953U2 (https=)
BR202017004898U2 (https=)